iShares Biotechnology ETF (NASDAQ:IBB) Reaches New 12-Month High – Time to Buy?

iShares Biotechnology ETF (NASDAQ:IBB) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $189.11 and last traded at $187.47, with a volume of 357942 shares traded. The stock had previously closed at $187.36.

iShares Biotechnology ETF Price Performance

The company has a 50-day simple moving average of $171.45 and a two-hundred day simple moving average of $171.04.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were issued a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date was Monday, June 15th.

Institutional Investors Weigh In On iShares Biotechnology ETF

A number of large investors have recently added to or reduced their stakes in the company. Citigroup Inc. raised its stake in shares of iShares Biotechnology ETF by 40.9% during the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after acquiring an additional 1,521,992 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of iShares Biotechnology ETF by 313.2% in the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock worth $276,526,000 after purchasing an additional 1,451,820 shares during the last quarter. Raymond James Financial Inc. increased its holdings in iShares Biotechnology ETF by 286.2% during the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after purchasing an additional 736,881 shares during the period. Bank of America Corp DE raised its position in iShares Biotechnology ETF by 10.8% during the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares during the last quarter. Finally, WestEnd Advisors LLC bought a new position in iShares Biotechnology ETF during the 4th quarter valued at approximately $106,276,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.